GeneDx Holdings Corp.
Close on Oct 19, 2026
- Market cap
- $1.97B
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Oct 27, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 3, 2026 | During market hours | $114.40M | $-0.60 | $0.01 |
| Q1 FY2026 Ended Mar 31, 2026 | May 4, 2026 | During market hours | $102.30M | $-2.16 | $-0.28 |
| Q4 FY2025 Ended Dec 31, 2025 | Jan 12, 2026 | During market hours | $121.00M | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Oct 28, 2025 | Before market open | $116.70M | $-0.27 | $0.49 |
| Q2 FY2025 Ended Jun 30, 2025 | Jul 29, 2025 | Before market open | $102.70M | $0.36 | – |
| Q1 FY2025 Ended Mar 31, 2025 | Apr 30, 2025 | Before market open | $87.10M | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Jan 13, 2025 | Before market open | $92.00M | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Oct 29, 2024 | Before market open | $76.90M | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Jul 30, 2024 | During market hours | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | Apr 29, 2024 | During market hours | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Jan 8, 2024 | Before market open | – | – | – |
Company guidance
Outlook given with results on Aug 3, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| Adjusted gross marginnon-GAAP | Third Quarter 2026 Guidance | 70% | New |
| Adjusted gross marginnon-GAAP | Full Year 2026 Guidance | 70% | Maintained |
| Exome and genome volume | Full Year 2026 Guidance | 30% growth | Raised |
| Exome and genome volume | Third Quarter 2026 Guidance | 33,200 | New |
| Adjusted net incomenon-GAAP | Third Quarter 2026 Guidance | $2.00M | New |
| Exome and genome revenue | Full Year 2026 Guidance | 20% growth | New |
| Revenue | Full Year 2026 Guidance | $475.00M to $490.00M | Maintained |
| Revenue | Third Quarter 2026 Guidance | $122.00M to $124.00M | New |
| Exome and genome revenue | Third Quarter 2026 Guidance | $110.00M to $112.00M | Lowered |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements GeneDx filed with the SEC
GeneDx Reports Second Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
GeneDx Nasdaq: WGS Q2 2026 Earnings Presentation August 2026 Exhibit 99.2
Results of operations · EX-99.2 to Form 8-K
GeneDx Names Mark Gardner President to Lead Its Next Phase of Scale and Growth
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
GeneDx Reports First Quarter 2026 Financial Results and Updates Full-Year Outlook
Results of operations · EX-99.1 to Form 8-K
(in thousands, except share and per share amounts)
Results of operations · EX-99.2 to Form 8-K
GeneDx Nasdaq: WGS Q1 2026 Earnings Presentation May 2026 Exhibit 99.3
Results of operations · EX-99.3 to Form 8-K
GeneDx Reports Fourth Quarter and Full Year 2025 Financial Results and
Results of operations · EX-99.1 to Form 8-K
GeneDx Nasdaq: WGS Q4 Earnings Presentation February 2026 Exhibit 99.2
Results of operations · EX-99.2 to Form 8-K
GeneDx Announces Preliminary 2025 Financial Results and Provides 2026 Guidance
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
GeneDx Nasdaq: WGS J.P. Morgan Healthcare Conference January 2026 San Francisco, California Exhibit 99.2
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
GeneDx Reports Third Quarter 2025 Financial Results and Business Highlights
Results of operations · EX-99.1 to Form 8-K
GeneDx (Nasdaq: WGS) 3Q 2025 Earnings Presentation October 28, 2025 Exhibit 99.2
Results of operations · EX-99.2 to Form 8-K
GeneDx Reports Second Quarter 2025 Financial Results and Business Highlights
Results of operations · EX-99.1 to Form 8-K
GeneDx (Nasdaq: WGS) 2Q 2025 Earnings Presentation July 29, 2025 Exhibit 99.2
Results of operations · EX-99.2 to Form 8-K
GeneDx Reports First Quarter 2025 Financial Results and Business Highlights
Results of operations · EX-99.1 to Form 8-K
GeneDx (Nasdaq: WGS) 1Q 2025 Earnings Presentation April 30, 2025 Exhibit 99.2
Results of operations · EX-99.2 to Form 8-K
GeneDx to Acquire Fabric Genomics, Enabling Decentralized, AI-Powered Testing at Global Scale
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
A new era in genomic medicine: decentralized AI-powered interpretation with centralized intelligence April 16, 2025 GeneDx to acquire Fabric Genomics Exhibit 99.2
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.2 to Form 8-K
GeneDx Reports Fourth Quarter and Full Year 2024 Financial Results and
Results of operations · EX-99.1 to Form 8-K
GeneDx (Nasdaq: WGS) 4Q 2024 Earnings Presentation February 18, 2025 Exhibit 99.2
Results of operations · EX-99.2 to Form 8-K
GeneDx Announces Preliminary 2024 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
GeneDx J.P. Morgan Healthcare Conference January 2025 San Francisco, California Exhibit 99.2
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
GeneDx Strengthens Executive Leadership Team with Bryan Dechairo Named Chief Operating Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
GeneDx Reports Third Quarter 2024 Financial Results and Business Highlights
Results of operations · EX-99.1 to Form 8-K
One test. Big picture. Brighter futures. October 29, 2024 GeneDx (Nasdaq: WGS) 3Q 2024 Earnings Presentation Exhibit 99.2
Results of operations · EX-99.2 to Form 8-K
GeneDx Reports Second Quarter 2024 Financial Results and Business Highlights
Results of operations · EX-99.1 to Form 8-K
One test. Big picture. Brighter futures. July 30, 2024 GeneDx (Nasdaq: WGS) 2Q 2024 Earnings Presentation Exhibit 99.2
Results of operations · EX-99.2 to Form 8-K
GeneDx Reports First Quarter 2024 Financial Results and Business Highlights
Results of operations · EX-99.1 to Form 8-K
One test. Big picture. Brighter futures. April 29, 2024 GeneDx (Nasdaq: WGS) Exhibit 99.2
Results of operations · EX-99.2 to Form 8-K
GeneDx Reports Fourth Quarter and Full Year 2023 Financial Results and Issues Guidance for Full Year 2024
Results of operations · EX-99.1 to Form 8-K
One test. Big picture. Brighter futures. February 20, 2024 GeneDx (Nasdaq: WGS) 4Q 2023 Earnings Presentation Exhibit 99.2
Results of operations · EX-99.2 to Form 8-K
GeneDx Announces Preliminary 2023 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
One test. Big picture. Brighter futures. 42nd Annual JPMorgan Healthcare Conference January 8, 2024 Katherine Stueland, President and Chief Executive Officer GeneDx (Nasdaq: WGS) Exhibit 99.2
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
GeneDx Reports Third Quarter 2023 Financial Results and Business Highlights
Material agreement · Agreement terminated · Results of operations · New financial obligation · Unregistered share sale · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Material agreement · Agreement terminated · Results of operations · New financial obligation · Unregistered share sale · EX-99.2 to Form 8-K
GeneDx Reports Second Quarter 2023 Financial Results and Business Highlights
Results of operations · EX-99.1 to Form 8-K
August 8, 2023 One Test: Miss Less. Discover More. GeneDx (Nasdaq: WGS) 2Q 2023 Earnings Presentation Exhibit 99.2
Results of operations · EX-99.2 to Form 8-K
GeneDx Regains Compliance with NASDAQ Minimum Bid Price Requirement
Other events · EX-99.1 to Form 8-K
GeneDx Reports First Quarter 2023 Financial Results and Business Highlights
Results of operations · EX-99.1 to Form 8-K
May 9, 2023 One Test: Miss Less. Discover More. GeneDx (Nasdaq: WGS) 1Q 2023 Earnings Presentation
Results of operations · EX-99.2 to Form 8-K